Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Saturday, February 3, 2018 7:43PM IST (2:13PM GMT)

(BW)(TAKEDA-PHARMACEUTICAL)

Takeda Reports 3rd Quarter FY2017 Results


Continued strong performance delivering double-digit earnings growth year-to-date; raising full-year guidance with Core Earnings margin expansion now projected at 300bps


Osaka, Japan

Takeda Pharmaceutical Company Limited (TOKYO:4502):

 

Underlying Revenue growth +6.7% led by Takeda's Growth Drivers

 
  • Underlying Revenue grew +6.7% year-to-date, with Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience and Emerging Markets) posting strong underlying revenue growth of +14.5%.
    • Gastroenterology +23.7% fueled by market share growth of ENTYVIO® and TAKECAB®.
    • Oncology +13.8% driven by the expansion of NINLARO® and ADCETRIS®, and the addition of revenue from ICLUSIG® and ALUNBRIG®.
    • Neuroscience +26.4% led by robust growth of TRINTELLIX® in the U.S.
    • Emerging Markets +1.9% with strong performance in Russia and Brazil offsetting temporary declines in China and the Middle East.
  • Underlying Revenue performance was driven by double-digit growth in the U.S. (U.S. +17.0%, Japan +1.3%, Europe & Canada +4.9%).
  • Reported revenue grew +4.1%, with the positive contribution from Takeda's Growth Drivers and favorable currency impact (+3.4pp) more than offsetting the negative impact of divestitures (-5.9pp).

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative

 
  • Underlying Core Earnings grew +32.8%, reflecting strong revenue growth and margin step-up of 3.9pp (+2.3pp gross margin; +1.6pp from OPEX margin).
  • Reported operating profit was up +48.2%, driven mainly by Core Earnings growth. It also includes one-time gains of 136.9 billion yen, including the sale of shares held in Wako Pure Chemical Ltd., disposal of real estate, and the transfer of additional long-listed products to Teva Takeda Yakuhin Ltd.
  • Underlying Core EPS was up +25.8%, and reported EPS increased +45.5% to 309 yen per share.

Net leverage improved due to steady progress on cash flow

 
  • Year-to-date Operating Free Cash Flow increased +25.1% to 152.1 billion yen, and the disposal of non-core assets generated an additional 142.9 billion yen of cash.
  • Net Debt / EBITDA dropped to 1.9x from 2.7x in March 2017.

James Kehoe, Chief Financial Officer, commented:
"Our Growth Drivers continued to power ahead and, together with our cost management initiatives, led to double-digit earnings growth and significant margin expansion. We are updating our full year guidance to reflect higher Velcade sales, and we now project Core Earnings margin expansion of approximately 300bps. Takeda will continue to deliver value to patients and shareholders as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."

 

Reported Results for Q3 YTD (April - December) FY2017

(billion yen)  

FY2016
Q3 YTD

 

FY2017
Q3 YTD

  % Growth vs Prior Year
      Reported   Underlying2
Revenue   1,315.8   1,369.6   +4.1%   +6.7%
Core Earnings1   228.3   292.7   +28.2%   +32.8%
Operating Profit   217.4   322.3   +48.2%   -
Net Profit3   165.7   240.9   +45.4%   -
EPS   212 yen   309 yen   +45.5%   +25.8%

1

  Core Earnings is calculated by deducting SG&A expenses and R&D expenses from reported Gross Profit. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2

  Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.

3

  Attributable to the owners of the company.
 

FY2017 Management Guidance: Raising full year underlying guidance to reflect higher Velcade sales;
now projecting Core Earnings growth in the "high twenties"

    Previous Guidance (growth %)
(Nov 1, 2017)
  Revised Guidance (growth %)
(Feb 1, 2018)
Underlying Revenue   Low single digit   Mid single digit
Underlying Core Earnings   High teen   High twenties
Underlying Core EPS   Mid teen   Mid twenties
Annual Dividend per Share   180 yen   180 yen
 

FY2017 Reported Forecast: Raising revenue & profit forecast to reflect Velcade upside;
EPS growth now at 36.9%. Forecast includes impacts from US Tax Legislation and Teva JV impairment

(billion yen)   Previous Forecast
(Nov 1, 2017)
 

Revised Forecast
(Feb 1, 2018)

  vs. FY2016
Revenue   1,720.0     1,745.0     +0.7%  
Core Earnings   267.5     289.5     +18.1%  
Operating Profit   200.0     218.7     +40.3%  
Net Profit   152.0     157.3     +36.9%  
EPS   195 yen     201 yen     +36.9%  
Exchange Rate (annual average)   1 US$=112 yen

1 euro=129 yen

  1 US$=112 yen

1 euro=130 yen

   
 

For more details on Takeda's FY2017 3rd quarter results and other financial information, please visit https://www.takeda.com/investors/reports/

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Investor Relations
Takeda Pharmaceutical Company Limited
Takashi Okubo, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com


More News from Takeda Pharmaceutical Company Limited

28/09/2018 12:25PM

Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or ...

25/09/2018 7:05PM

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

– ALTA-1L Met its Primary Endpoint Showing Superiority in Blinded Independent Review Committee-Assessed Progression-Free Survival Compared to Crizotinib – – Data Will Be Presented During the ...

22/09/2018 10:20AM

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full ...

Similar News

19/10/2018 9:30AM Image

ISG Positions L&T Technology Services as Global Leader in the First Ever Service Provider Ranking on Product, Process and Platform Engineering

L&T Technology Services (NSE: LTTS), a leading global pure play engineering services company, has been rated as a Leader in 6 market categories across 3 industries for the U.S. market in the inaugural edition of ...

No Image

18/10/2018 7:24PM

आईडब्ल्यूबीआई ने वेल (डब्ल्यूईएलएल) पोर्टफोलियो के लिए सलाहकारों का अंतरराष्ट्रीय नेटवर्क पेश किया

दि इंटरनेशनल वेल बिल्डिंग इंस्टीट्यूट™ (आईडब्ल्यूबीआई™) ने आज एक अंतरराष्ट्रीय सलाह (एडवाइज़री) तैयार करने का एलान किया। यह वेल पोर्टफोलियो™ पाथवे पायलट को आकार देने और इसे लागू करने का काम ...